title: Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults.
abstract: Pantoprazole, an irreversible proton pump inhibitor, may be administered with cisapride, a prokinetic agent. As increased cisapride concentrations may result in longer electrocardiogram (ECG) QTc intervals, a crossover study was conducted in healthy subjects to evaluate the oral pharmacokinetic interaction between cisapride (20 mg) and pantoprazole (40 mg). After dosing, serial blood samples and 12-lead ECGs were collected, and cisapride plasma concentrations were quantitated. For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours. Pantoprazole coadministration did not alter cisapride AUC or other pharmacokinetic parameters except for a slight 17% decrease in Cmax' resulting in 90% confidence limits of 79% to 88%, which were marginally outside strict bioequivalence limits. In addition, cisapride did not affect ECG QTc intervals, with or without pantoprazole. Therefore, no dosage adjustment is needed when pantoprazole and cisapride are coadministered.
authors.affiliation: Wyeth-Ayerst Research, Philadelphia, Pennsylvania, USA.
authors.forename: G M
authors.initials: GM
authors.lastname: Ferron
authors.forename: J C
authors.initials: JC
authors.lastname: Paul
authors.forename: R J
authors.initials: RJ
authors.lastname: Fruncillo
authors.forename: P T
authors.initials: PT
authors.lastname: Martin
authors.forename: L
authors.initials: L
authors.lastname: Yacoub
authors.forename: P R
authors.initials: PR
authors.lastname: Mayer
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D001562:Benzimidazoles / Q000009:adverse effects / Q000494:pharmacology*; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D020117:Cisapride / Q000009:adverse effects / Q000097:blood*; D018592:Cross-Over Studies; D004347:Drug Interactions; D004562:Electrocardiography / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000097:blood*; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D013454:Sulfoxides / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D005765:Gastrointestinal Agents; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole; D020117:Cisapride